Presentation is loading. Please wait.

Presentation is loading. Please wait.

An Innovative Technique to Oxygenate and Ventilate

Similar presentations


Presentation on theme: "An Innovative Technique to Oxygenate and Ventilate"— Presentation transcript:

1 An Innovative Technique to Oxygenate and Ventilate
Dr Ayush Gupta DTCD, DNB, DM Fellow Department of Pulmonary, Critical Care and Sleep Medicine Safdarjang Hospital

2 Case Summary 19 year old female Normal milestones, no co-morbidities
Presented with chief complaints of:- progressively increasing breathlessness – 7 years cough, sputum, hemoptysis on and off – 7 years History of ATT intake 3 times – 2006, 2011, 2014 Sputum for AFB stain – Negative all three times Diagnosed as having post tubercular bilateral bronchiectasis with type 2 respiratory failure by private practioner Referred to Safdarjang hospital for further management

3 Case summary – Xray Chest

4 CT Chest – mediastinal window

5 CT Chest – Mediastinal window

6 CT chest – Mediastinal window

7 CT Chest – Mediastinal window

8 CT Chest- Lung window

9 CT Chest – Lung window

10 CT Chest – Lung window lower cuts

11 Case Summary - investigations
Hb-10.6gm/dl; TLC-5600; KFT, LFT- WNL Sputum for AFB stain and culture – Negative Gene Xpert Mtb – Negative Total Serum IgE – 104 Specific IgE/ IgG against aspergillus – Negative Cystic fibrosis work up – Negative (CFTR; Sweat Chloride) Mantoux test 1 TU – 7mm induration Serum ACE – 86 units/ml (elevated); S Ca2+ - Norm ABG on 21% FiO2– ph – 7.331; pCO2 – 73; pO2 – 35; HCO3 – 33

12 Case Summary No biopsy or TBNA was possible in view of type 2 respiratory failure Vitals – Temp – 98 degree F Pulse – 132/min RR – 36/min BP- 120/60 mm of hg SpO2 – 66% on room air and 89% on 6l via nasal prongs Provisional diagnosis - ?Stage 4 Sarcoidosis / Bilateral bronchiectasis/ Chronic type 2 respiratory failure was made (Negative Mantoux, Bilateral mediastinal adenopathy; Extensive fibrocystic lung lesions; Sputum for AFB negative; Elevated ACE)

13 Treatment Patient had received 3 courses of ATT – good compliance; persistent symptoms Received multiple courses of systemic steroids in view of obstructive airway disease – no response Steroids were discontinued on presentation to our unit; started on inhaled bronchodilators + ICS In view of type 2 RF, tachypnea and tachycardia, patient was put on non invasive mechanical ventilation Ipap- 22; Epap- 6; Fio2- 40%

14 NIV machine – with in built oxygen air blender to deliver desired FiO2

15 ABG – Pre and Post NIV Pre NIV Post NIV Fio2- 21% 21% pH – 7.331 7.382
pCO 58.2 pO2- 35 40 HCO3 – 33.3 29.5 So2- 65% 71%

16 Symptomatic improvement
Patient was gradually weaned to nocturnal NIV (8-10 hrs) with daytime oxygen therapy Her dyspnea improved, tachycardia and tachypnea reduced (HR-110; RR – 25 at rest on oxygen) Patient was planned for home nocturnal NIV and domiciliary oxygen therapy Was also given option of lung transplantation

17 The issues Patient required 5-6 litres/min flow rate via nasal prongs at rest to keep SpO2 of 88-90% - difficult to manage at home and will result in limitation of physical activity Patient bought Respironics Bipap machine with ST mode and when oxygen supplementation was added via cannula through full face mask, flow requirements were 10-11L/min to maintain SpO2 of 90% on NIV – due to dilution of oxygen flow in the NIV mask as a result of high NIV pressures

18 The issues Patient remained hypercapnic at maximal tolerable pressures – PaC02 was mm of Hg

19 Methods to add oxygen in the NIV circuit when not using NIV machine with blender

20 What next?? Not able to oxygenate at rest
Not able to mix adequate oxygen in the NIV circuit Persistent hypercapnea at maximal tolerable pressures

21 Options Ask patient to buy home oxygen concentrator with 11L/min flow rate capacity – tried but did not work with NIV as it was not 100% pure oxygen; costly Ask patient to buy home NIV machine with in built blender – extremely costly; requires pressurised oxygen source through cylinders; cannot be used with O2 concentrators Oxygen conserving devices such as pendant device – solved the issue of daytime high oxygen requirement with nasal prongs but the problem with NIV remained; patient found it obtrusive

22 Not able to discharge patient home
Patient was in stable, chronic type 2 respiratory failure but required NIV machine with in built blender She was bed bound with exertional desaturation limiting her physical activity Bilateral extensive bronchiectasis limited her long term survival

23 The final solution – Transtracheal oxygen using Minitrach catheter

24 Transtracheal oxygen (TTO)
Transtracheal oxygen is delivered via a catheter inserted through cricothyroid membrane or between 1st and 2nd tracheal rings Usual technique is a surgically created tract between the first and the second tracheal rings in OT by a surgeon (T10 Fast Tract procedure kit; SCOOP system; USA; TTO2.com) SCOOP transtracheal catheters are placed in the tract to deliver oxygen directly into trachea; Tract matures; SCOOP catheters changed monthly Costly; Patented; Surgical procedure; Not available

25 Minitrach transtracheal catheter
Inserted through cricothyroid membrane using Seldinger technique bedside by Pulmonologist/ Critical care specialist Easy to insert; no guidance required; voice preserved No major complications; well accepted by the patient Either 100% oxygen or air oxygen mixture can be insufflated through transtracheal catheter OD of 4mm and length of 6 cms; 10 french suction catheter can pass through lumen Not routinely used for TTO delivery

26 TTO - Advantages Acts as oxygen conserving device with the trachea acting as reservoir – reduces oxygen demand from the source by 40-50% Reduces the anatomical dead space compartment by flushing out CO2 proximal to the tip of catheter in the trachea – changes Vd/Vt ratio and reduces PaCO2 Reduces minute ventilation requirement by 20-30% Minute ventilation sparing effect of TGI reduces work of breathing O2 does not get diluted with the NIV flows in the face mask

27 Status of the patient post TTO
Daytime – O2 inhalation at 2 l/min via TTC at rest; 3l/min while walking; able to do all her routine activities and walk for about 500 metres at a stretch Nocturnal NIV – Ipap- 22, Epap- 6, O2 inhalation via TTC at 3l/min with NIV Pulse- 110/min, RR- 24/min ABG – pH ; PaCO2- 50; PaO2- 42; HCO3- 28 Vocalising and communicating Discharged home safely Awaiting lung transplant

28 Transtracheal catheter in situ

29 O2 inhalation via TTC at 2-3L/min

30 Case report Accepted for publication in IJCDAS in 2015
2 patients with chronic type 2 RF on high intensity NIV with high pressure requirements Required high flow rates of supplemental oxygen with NIV Had persistent hypercapnia on maximal tolerated pressures NIV with TTO using minitrach catheter Both patients had significant reduction in O2 requirement from source, reduced PaCO2 levels and were made ambulatory at home

31 Newer potential indications
Early weaning of ARDS patients – successfully tried in one patient of H1N1 severe ARDS Acute exacerbation of COPD with hypercapnea – as an adjunct to NIV Acute exacerbation of IPF with high FiO2 requirements - tried in one patient while awaiting response to high dose steroids Traumatic brain injury with COPD – tried in one patient to maintain normocapnea and reduce WOB Neuromuscular disorders with type 2 RF - with NIV

32 Complications Bronchial mucosal damage – due to impact of the jet stream as well as physical impact of the catheter tip on the tracheal wall Inadequate humidification of the inspired gas -catheter blocks due to thick, retained secretions Hemoptysis- tracheal wall injury or faulty insertion technique Usually minor; Catheter well tolerated

33 Summary Transtracheal oxygen therapy via minitrach catheter is an innovative technique to oxygenate and ventilate the patient Acts as an oxygen conserving device with trachea as the reservoir; reduces oxygen demand from source Reduces anatomical dead space, changes Vd/Vt ratio, reduces minute ventilation requirement, WOB and PaCO2 Easy to insert; Good compliance; Speech preservation Potential use in a variety of clinical situations NIV with TTO is an experimental modality with promising results and sound physiological basis

34 Thank You

35

36


Download ppt "An Innovative Technique to Oxygenate and Ventilate"

Similar presentations


Ads by Google